Omondi Michelle Atieno1, Sylvia Opanga1, Antony Martin2,3, Amanj Kurdi4,5, Brian Godman2,4,6,7. 1. a Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy , University of Nairobi , Nairobi , Kenya. 2. b Health Economics Centre , University of Liverpool Management School , Liverpool , UK. 3. c HCD Economics , The Innovation Centre , Daresbury , UK. 4. d Strathclyde Institute of Pharmacy and Biomedicial Sciences , University of Strathclyde , Glasgow , UK. 5. e Department of Pharmacology , College of Pharmacy, Hawler Medical University , Erbil , Iraq. 6. f Division of Clinical Pharmacology , Karolinska, Karolinska Institutet , Stockholm , Sweden. 7. g School of Pharmaceutical Sciences , Universiti Sains Malaysia , Penang , Malaysia.
Abstract
BACKGROUND: Currently the majority of cancer deaths occur in low- and middle-income countries, where there are appreciable funding concerns. In Kenya, most patients currently pay out of pocket for treatment, and those who are insured are generally not covered for the full costs of treatment. This places a considerable burden on households if family members develop cancer. However, the actual cost of cancer treatment in Kenya is unknown. Such an analysis is essential to better allocate resources as Kenya strives towards universal healthcare. OBJECTIVES: To evaluate the economic burden of treating cancer patients. METHOD: Descriptive cross-sectional cost of illness study in the leading teaching and referral hospital in Kenya, with data collected from the hospital files of sampled adult patients for treatment during 2016. RESULTS: In total, 412 patient files were reviewed, of which 63.4% (n = 261) were female and 36.6% (n = 151) male. The cost of cancer care is highly dependent on the modality. Most reviewed patients had surgery, chemotherapy and palliative care. The cost of cancer therapy varied with the type of cancer. Patients on chemotherapy alone cost an average of KES 138,207 (USD 1364.3); while those treated with surgery cost an average of KES 128,207 (1265.6), and those on radiotherapy KES 119,036 (1175.1). Some patients had a combination of all three, costing, on average, KES 333,462 (3291.8) per patient during the year. CONCLUSION: The cost of cancer treatment in Kenya depends on the type of cancer, the modality, cost of medicines and the type of inpatient admission. The greatest contributors are currently the cost of medicines and inpatient admissions. This pilot study can inform future initiatives among the government as well as private and public insurance companies to increase available resources, and better allocate available resources, to more effectively treat patients with cancer in Kenya. The authors will be monitoring developments and conducting further research.
BACKGROUND: Currently the majority of cancer deaths occur in low- and middle-income countries, where there are appreciable funding concerns. In Kenya, most patients currently pay out of pocket for treatment, and those who are insured are generally not covered for the full costs of treatment. This places a considerable burden on households if family members develop cancer. However, the actual cost of cancer treatment in Kenya is unknown. Such an analysis is essential to better allocate resources as Kenya strives towards universal healthcare. OBJECTIVES: To evaluate the economic burden of treating cancerpatients. METHOD: Descriptive cross-sectional cost of illness study in the leading teaching and referral hospital in Kenya, with data collected from the hospital files of sampled adult patients for treatment during 2016. RESULTS: In total, 412 patient files were reviewed, of which 63.4% (n = 261) were female and 36.6% (n = 151) male. The cost of cancer care is highly dependent on the modality. Most reviewed patients had surgery, chemotherapy and palliative care. The cost of cancer therapy varied with the type of cancer. Patients on chemotherapy alone cost an average of KES 138,207 (USD 1364.3); while those treated with surgery cost an average of KES 128,207 (1265.6), and those on radiotherapy KES 119,036 (1175.1). Some patients had a combination of all three, costing, on average, KES 333,462 (3291.8) per patient during the year. CONCLUSION: The cost of cancer treatment in Kenya depends on the type of cancer, the modality, cost of medicines and the type of inpatient admission. The greatest contributors are currently the cost of medicines and inpatient admissions. This pilot study can inform future initiatives among the government as well as private and public insurance companies to increase available resources, and better allocate available resources, to more effectively treat patients with cancer in Kenya. The authors will be monitoring developments and conducting further research.
Entities:
Keywords:
Cancer; H51; I18; J18; Kenya; L33; chemotherapy; cost of illness; direct medical costs; medicine costs; radiotherapy
Authors: Marina Morgado Garcia; Pamela Santos Azevedo; Andrew Mirelman; Leandro Pinheiro Safatle; Roberto Iunes; Marion Clark Bennie; Brian Godman; Augusto Afonso Guerra Junior Journal: Front Pharmacol Date: 2020-04-14 Impact factor: 5.810
Authors: Wânia Cristina da Silva; Brian Godman; Francisco de Assis Acúrcio; Mariângela Leal Cherchiglia; Antony Martin; Konrad Maruszczyk; Jans Bastos Izidoro; Marcos André Portella; Agner Pereira Lana; Orozimbo Henriques Campos Neto; Eli Iola Gurgel Andrade Journal: Appl Health Econ Health Policy Date: 2021-01-28 Impact factor: 2.561
Authors: Louise Kathini Makau-Barasa; Sandra Greene; N A Othieno-Abinya; Stephanie B Wheeler; Asheley Skinner; Antonia V Bennett Journal: Health Res Policy Syst Date: 2020-01-07
Authors: Fortunata Songora Makene; Richard Ngilangwa; Cristina Santos; Charlotte Cross; Twalib Ngoma; Phares G M Mujinja; Marc Wuyts; Maureen Mackintosh Journal: BMC Health Serv Res Date: 2022-02-12 Impact factor: 2.655